Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief Business Officer. In this role, Mr. Avagliano will serve as a member of the G1 executive team a...
CDK4/6 inhibitors, Pfizer’s (PFE) Ibrance and Eli Lilly’s (LLY) Verzenio, have already made their mark in the breast cancer space. And now the market is waiting for CDK4/6 inhibitors to penetrate other oncology indications. One such closely watched investigational compound is G...
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with this Read more ...
Gainers: MoneyGram International (NASDAQ: MGI ) +106% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +33% . G1 Therapeutics (NASDAQ: GTHX ) +26% . SunPower Corporation (NASDAQ: SPWR ) +24% . Sundance Energy Australia (NASDAQ: SNDE ) +20% . Cortexyme (NASDAQ: CRTX...
MoneyGram International (NASDAQ: MGI ) +152% after partnering with Ripple. More news on: MoneyGram International, Inc., Cesca Therapeutics Inc., G1 Therapeutics, Inc., Stocks on the move, Read more ...
- Detailed data from this trial will be presented at a medical meeting later this year - RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results ...
RESEARCH TRIANGLE PARK, N.C., June 14, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that an analysis of patient-reported outcomes (PRO) data from three Phase 2 trials of trilaciclib in small cell lung cancer patients will ...
- Garry Nicholson to serve as new board chair - - Sir Andrew Witty, Fredric Eshelman, Pharm.D. and prior chair Seth Rudnick, M.D. re-elected - RESEARCH TRIANGLE PARK, N.C., June 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, t...
RESEARCH TRIANGLE PARK, N.C., June 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the Raymond James Life Sciences and MedTech Conf...
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a r...
News, Short Squeeze, Breakout and More Instantly...
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know: Accor...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...